S&P 500   4,599.27 (+0.30%)
DOW   36,217.85 (+0.28%)
QQQ   391.85 (+0.36%)
AAPL   195.52 (+0.64%)
MSFT   373.23 (+0.61%)
META   331.45 (+1.49%)
GOOGL   134.81 (-1.55%)
AMZN   147.24 (+0.25%)
TSLA   243.46 (+0.34%)
NVDA   476.05 (+2.17%)
NIO   7.40 (-1.20%)
BABA   72.30 (-0.04%)
AMD   129.17 (+0.62%)
T   16.84 (-1.46%)
F   11.04 (+2.03%)
MU   75.06 (+1.91%)
CGC   0.76 (+5.40%)
GE   120.36 (+0.74%)
DIS   92.69 (+0.37%)
AMC   6.92 (+1.47%)
PFE   28.72 (+0.31%)
PYPL   58.94 (+0.79%)
XOM   99.37 (+0.97%)
S&P 500   4,599.27 (+0.30%)
DOW   36,217.85 (+0.28%)
QQQ   391.85 (+0.36%)
AAPL   195.52 (+0.64%)
MSFT   373.23 (+0.61%)
META   331.45 (+1.49%)
GOOGL   134.81 (-1.55%)
AMZN   147.24 (+0.25%)
TSLA   243.46 (+0.34%)
NVDA   476.05 (+2.17%)
NIO   7.40 (-1.20%)
BABA   72.30 (-0.04%)
AMD   129.17 (+0.62%)
T   16.84 (-1.46%)
F   11.04 (+2.03%)
MU   75.06 (+1.91%)
CGC   0.76 (+5.40%)
GE   120.36 (+0.74%)
DIS   92.69 (+0.37%)
AMC   6.92 (+1.47%)
PFE   28.72 (+0.31%)
PYPL   58.94 (+0.79%)
XOM   99.37 (+0.97%)
S&P 500   4,599.27 (+0.30%)
DOW   36,217.85 (+0.28%)
QQQ   391.85 (+0.36%)
AAPL   195.52 (+0.64%)
MSFT   373.23 (+0.61%)
META   331.45 (+1.49%)
GOOGL   134.81 (-1.55%)
AMZN   147.24 (+0.25%)
TSLA   243.46 (+0.34%)
NVDA   476.05 (+2.17%)
NIO   7.40 (-1.20%)
BABA   72.30 (-0.04%)
AMD   129.17 (+0.62%)
T   16.84 (-1.46%)
F   11.04 (+2.03%)
MU   75.06 (+1.91%)
CGC   0.76 (+5.40%)
GE   120.36 (+0.74%)
DIS   92.69 (+0.37%)
AMC   6.92 (+1.47%)
PFE   28.72 (+0.31%)
PYPL   58.94 (+0.79%)
XOM   99.37 (+0.97%)
S&P 500   4,599.27 (+0.30%)
DOW   36,217.85 (+0.28%)
QQQ   391.85 (+0.36%)
AAPL   195.52 (+0.64%)
MSFT   373.23 (+0.61%)
META   331.45 (+1.49%)
GOOGL   134.81 (-1.55%)
AMZN   147.24 (+0.25%)
TSLA   243.46 (+0.34%)
NVDA   476.05 (+2.17%)
NIO   7.40 (-1.20%)
BABA   72.30 (-0.04%)
AMD   129.17 (+0.62%)
T   16.84 (-1.46%)
F   11.04 (+2.03%)
MU   75.06 (+1.91%)
CGC   0.76 (+5.40%)
GE   120.36 (+0.74%)
DIS   92.69 (+0.37%)
AMC   6.92 (+1.47%)
PFE   28.72 (+0.31%)
PYPL   58.94 (+0.79%)
XOM   99.37 (+0.97%)

OncoCyte Stock Price, News & Analysis (NASDAQ:OCX)

$3.16
-0.68 (-17.71%)
(As of 01:34 PM ET)
Compare
Today's Range
$2.83
$3.75
50-Day Range
$2.08
$4.26
52-Week Range
$2.08
$10.00
Volume
30,293 shs
Average Volume
18,591 shs
Market Capitalization
$26.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.87

OncoCyte MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
15.4% Upside
$3.87 Price Target
Short Interest
Bearish
2.67% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.78mentions of OncoCyte in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.59) to ($3.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.50 out of 5 stars

Medical Sector

929th out of 960 stocks

Diagnostic Substances Industry

9th out of 10 stocks


OCX stock logo

About OncoCyte Stock (NASDAQ:OCX)

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OCX Stock Price History

OCX Stock News Headlines

An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
OncoCyte Corp OCX
Oncocyte Reports Third Quarter 2023 Financial Results
Oncocyte to Announce Third Quarter 2023 Financial Results
Recent Reports Are A Wake-Up Call For Investors
As the demand for lithium, an essential element to the energy revolution, increases globally, researchers are projecting a supply deficit as early as 2025. This has sparked a worldwide "gold rush" to find and develop new sources of this critical metal. Savvy investors are paying attention as mining companies race to meet this critical deadline.
Oncocyte Reports Second Quarter 2023 Financial Results
Oncocyte Announces 1-For-20 Reverse Stock Split
See More Headlines
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2023
Today
12/08/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/29/2024

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCX
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.87
High Stock Price Target
$5.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+5.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-72,900,000.00
Net Margins
-3,923.58%
Pretax Margin
-1,427.20%

Debt

Sales & Book Value

Annual Sales
$1.46 million
Cash Flow
$0.84 per share
Book Value
$5.78 per share

Miscellaneous

Free Float
8,101,000
Market Cap
$30.24 million
Optionable
Optionable
Beta
1.81
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joshua Riggs (Age 40)
    President, CEO & Director
    Comp: $373.2k
  • Mr. James Liu (Age 27)
    Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer
    Comp: $192.48k
  • Dr. Ekkehard Schutz M.D.
    Ph.D., Chief Science Officer
  • Mr. Yuh-Min Chiang Ph.D.
    Senior Vice President of R&D and Product Development
  • Ms. Sandra O'Donald
    Senior Vice President of Business Operations
  • Dr. Michael D. West Ph.D. (Age 70)
    Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.
  • Peter Hong
    Secretary
  • Ms. Sara Riordan
    Director of Medical Education














OCX Stock Analysis - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" OCX shares.
View OCX analyst ratings
or view top-rated stocks.

What is OncoCyte's stock price target for 2024?

3 analysts have issued 1 year price objectives for OncoCyte's shares. Their OCX share price targets range from $3.00 to $5.00. On average, they predict the company's stock price to reach $3.87 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts price targets for OCX
or view top-rated stocks among Wall Street analysts.

How have OCX shares performed in 2023?

OncoCyte's stock was trading at $6.4180 at the start of the year. Since then, OCX shares have decreased by 47.8% and is now trading at $3.35.
View the best growth stocks for 2023 here
.

When is OncoCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our OCX earnings forecast
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NASDAQ:OCX) released its quarterly earnings data on Thursday, November, 9th. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($1.52) by $0.95. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.40 million. OncoCyte had a negative net margin of 3,923.58% and a negative trailing twelve-month return on equity of 77.26%.

When did OncoCyte's stock split?

OncoCyte's stock reverse split on the morning of Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of OncoCyte own?
Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include AWM Investment Company Inc. (8.71%), Defender Capital LLC. (1.39%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends
.

How do I buy shares of OncoCyte?

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OCX) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -